<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:department>Pure and Applied Chemistry</gtr:department><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A212D47C-49A9-43DB-B299-B6FA63AAAB51"><gtr:id>A212D47C-49A9-43DB-B299-B6FA63AAAB51</gtr:id><gtr:name>Renishaw Diagnostics Ltd</gtr:name><gtr:address><gtr:line1>Nova technology Park</gtr:line1><gtr:line2>5 Robroyston Oval</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>g33 1AP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CB6A4B70-3F28-45DC-B53B-BF92BE14043E"><gtr:id>CB6A4B70-3F28-45DC-B53B-BF92BE14043E</gtr:id><gtr:firstName>Duncan</gtr:firstName><gtr:surname>Graham</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5778B682-4468-433C-BE64-14230E1E7231"><gtr:id>5778B682-4468-433C-BE64-14230E1E7231</gtr:id><gtr:firstName>Pasquale</gtr:firstName><gtr:surname>Maffia</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EEE5331C-7D11-4578-BAC5-788C990A6C47"><gtr:id>EEE5331C-7D11-4578-BAC5-788C990A6C47</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:surname>McInnes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4D0B2BB2-D7BA-4672-A3C1-925C8077EDA0"><gtr:id>4D0B2BB2-D7BA-4672-A3C1-925C8077EDA0</gtr:id><gtr:firstName>Naveed</gtr:firstName><gtr:surname>Sattar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3E91007A-C382-4933-9141-61911A5056ED"><gtr:id>3E91007A-C382-4933-9141-61911A5056ED</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Garside</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/AF6F1E66-72CA-45CC-85EA-60FCD5F61D57"><gtr:id>AF6F1E66-72CA-45CC-85EA-60FCD5F61D57</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Girolami</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D017114E-4EFF-4360-9F26-9754BF40A9A2"><gtr:id>D017114E-4EFF-4360-9F26-9754BF40A9A2</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Faulds</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FL014165%2F1"><gtr:id>B00304EB-9262-4414-96C8-C2093EC279A6</gtr:id><gtr:title>In Situ Nanoparticle Assemblies for Healthcare Diagnostics and Therapy</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/L014165/1</gtr:grantReference><gtr:abstractText>There is a growing need for clinicians to be able to diagnose and prescribe therapy according to an individual's healthcare needs and potential responses. To allow this personalised medicine approach to be fulfilled, new technologies allowing rapid and accurate detection of biomarkers indicative of specific diseases are needed and to be available to clinicians to aid in their management of disease. This proposal aims to bring together physical scientists working on nanoparticles capable of detecting biomarkers at ultralow concentrations with information technologists capable of interpreting and presenting data from these complex assays to the clinical partners who are interested in how best to utilise this new information in improved healthcare practice. The basis of the proposal is to create an in vitro diagnostic assay at first which is capable of detecting multiple biomarkers in a patient's sample which allows the clinician to produce a risk profile of the patient. A second aspect of the research is to investigate in vivo imaging by SERS for specific biomarkers and in a multiplexed manner. The disease we are targeting is cardiovascular disease which covers atherosclerotic plaques. Risk of atherosclerosis is identified by increased levels of specific biomarkers, however, atherosclerosis is characterised by a localised rather than a systemic immune response. Therefore the measurement of biomarkers for in vitro prediction will be investigated in parallel to quantification of vascular inflammation and the development of a therapeutic approach to convey treatments directly to the affected vessel. The assays will be based on surface enhanced Raman scattering (SERS) and use metallic nanoparticles. The output will be in the form of a vibrational spectrum which will contain a high degree of information relating to the relative quantitation of each of the specific biomarkers being investigated. Two types of in vitro assay will be investigated with one of them carrying forward for in vivo imaging. The in vivo assay will recognise the target and through interpretation of the signal allow a decision to be made whether to induce a therapeutic action. The action we are proposing is a photothermal response from an assembly of the nanoparticles triggered by the specific biomarker being interrogated. This makes the response highly specific to that biomarker and will offer a new way to manage atherosclerosis.</gtr:abstractText><gtr:potentialImpactText>There are a number of different communities who will benefit from the research outputs and improved capacity from this research and again this grouping of communities will be included in our User Engagement Strategy. The most immediate beneficiaries will be the general public who will ultimately be exposed to improved capability in terms of healthcare diagnostics and management. We are proposing to integrate physical sciences, data interpretation and clinical utilisation. The end result from this will be an improved opportunity for clinicians to manage the disease types we are concentrating on and in turn pass on these benefits and improved capability to the patients. This will result in shortened hospital time with more appropriate administration and prescription of therapeutic drugs which in turn minimises potential side effects to the patient and also improves the economics of healthcare by reducing the amount of drugs necessary for prescription. That is of course assuming that the prognosis from the analysis is that minimal drug intervention can be employed. We also see this as a significant benefit in terms of quality of life and in terms of health and wellbeing for the general public. The clinical partners are influential in terms of medical research and medical policy making. e.g McInnes is chair of the newly created Arthritis Research UK New Agents Committee, leader of the CSO/Pfizer co funded Scottish Early Arthritis Research Programme and has strong links with the pharmaceutical industry serving as chair or participant in a range of Industry drug development programmes at the global level. These examples provide evidence of the potential for significant impact. In addition to specific healthcare outcomes we also see opportunities for engagement with a range of industry partners who will be interested in different aspects of the impact from this research. This will include manufacturers who are capable of producing systems necessary for the combined measurements we are proposing (project partner), reagent suppliers who are interested in the specific chemistries employed, software developers who are looking to implement new software approaches to medical problems and also to the pharmaceutical companies who are interested in more efficient prescription of their medicines. We see impact in all of these sectors and will look to engage with these different areas of exploitation as we implement our Impact strategy. Three of the investigators have direct experience of spin-out which is a benefit to both the project and also the end user community. We are uncertain whether there are spin-out opportunities directly arising from any of the intellectual property which will be created during the project however this is something which we will regularly review and use our experience to inform our decision making process on as we progress.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2014-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2992296</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Visit (Gavinburn Primary School - Old Kilpatrick, UK)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AE481A2F-8212-4BE3-9E69-E00ED1B173B7</gtr:id><gtr:impact>School Visit to the Gavinburn Primary School, Old Kilpatrick, UK (02.03.2016) - We organized a stand with hands-on activities on 'Atherosclerosis' (Total attendees: 104 children P4-P7). Our group portrayed the importance of studying cardiovascular disease running a 'science stall' with hands-on activities for children. The team aim to investigate how to improve the diagnosis and treatment of vascular inflammation. Children were invited to interact with a hyper-realistic artery, play a specifically-designed computer game, and to create their own &amp;quot;good&amp;quot; or &amp;quot;bad&amp;quot; immune cell from clay, paint it and take it home as a souvenir.</gtr:impact><gtr:outcomeId>56d9d94559daa7.95248667</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Panto Science: The Periodic Fable</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4A2C5FE6-D87B-4647-A76D-E114E2F05054</gtr:id><gtr:impact>Our station interacted with 90 kids. My group portrayed the importance of studying cardiovascular disease running a 'science stall' with hands-on activities for children prior to the performance. Children were invited to interact with a hyper-realistic artery. Children were also invited to play a specifically-designed computer game, and to create their own &amp;quot;good&amp;quot; or &amp;quot;bad&amp;quot; immune cell from clay, paint it and take it home as a souvenir.

All the children are now aware of the main risk factors leading to CVD.</gtr:impact><gtr:outcomeId>5675b69455e632.24083132</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://m.eveningtimes.co.uk/news/14136701.What_s_behind_pantomime__Science_show_will_reveal_all/?ref=rss</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Glasgow Science Festival 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4C64773A-9D87-433F-ACA2-14DCECF3EF6F</gtr:id><gtr:impact>On 11th-12th June 2016, we portrayed the importance of studying cardiovascular disease running a 'Nanomate science stall' with hands-on activities at the Glasgow Science Festival. The team aim to investigate how nanoparticles could be used to improve the diagnosis and treatment of vascular inflammation. The two exciting days of science took place at the Kelvingrove Museum in Glasgow with activities supported by supported by Glasgow Polyomics (Wellcome Trust grant 105614/Z/14/Z) and the British Heart Foundation.
The 'Nanomate' stall interacted with over 1000 people in 2 days, with 11 researchers involved, 14 kg of clay used, 300 gift boxes distributed and over 250 'I like it' stickers on the evaluation boards.</gtr:impact><gtr:outcomeId>578d3a5d7c2374.29348360</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.polyomics.gla.ac.uk/event-nanomate.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Explorathon' night at the Glasgow Science Centre 2015</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>89117242-136A-4299-BCA9-04CCB119901B</gtr:id><gtr:impact>Over 3000 members of the public attended the events. Our station interacted with 500 kids and adults. Our group portrayed the importance of studying cardiovascular disease running a 'science stall' with hands-on activities for children and adults. The team aim to investigate how to improve the diagnosis and treatment of vascular inflammation. Both children and adults were invited to interact with a hyper-realistic artery. Children were also invited to play a specifically-designed computer game, and to create their own &amp;quot;good&amp;quot; or &amp;quot;bad&amp;quot; immune cell from clay, paint it and take it home as a souvenir.


All the children are now aware of the main risk factors leading to CVD.</gtr:impact><gtr:outcomeId>5675ae58589a95.97954259</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.explorathon.co.uk/glasgow</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>'Explorathon' night at the Glasgow Science Centre 2016</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7433FD6C-C9AC-432E-A2F9-369633E454E9</gtr:id><gtr:impact>Over 2000 members of the public attended the events. Our station interacted with 400 kids and adults. Our group portrayed the importance of studying cardiovascular disease running a 'science stall' with hands-on activities for children and adults. The team aim to investigate how to improve the diagnosis and treatment of vascular inflammation. Both children and adults were invited to interact with a hyper-realistic artery. Children were also invited to play a specifically-designed computer game, and to create their own &amp;quot;good&amp;quot; or &amp;quot;bad&amp;quot; immune cell from clay, paint it and take it home as a souvenir.</gtr:impact><gtr:outcomeId>57f8f81f902044.97352854</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.explorathon.co.uk/glasgow</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Midlothian Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C0EFB92A-70C9-42F2-87CB-E3D91183B8BF</gtr:id><gtr:impact>Midlothian Science Festival, Newtongrange Library, Dalkeith, UK (14.10.2015) - We organized a stand with hands-on activities on 'Atherosclerosis: In SERS we trust' (Total attendees: 150 - Our stand engaged with approximately 67 children and 40 adults, including some individuals with severe ADHD). Our group portrayed the importance of studying cardiovascular disease running a 'science stall' with hands-on activities for children and adults. The team aim to investigate how to improve the diagnosis and treatment of vascular inflammation. Both children and adults were invited to interact with a hyper-realistic artery. Children were also invited to play a specifically-designed computer game, and to create their own &amp;quot;good&amp;quot; or &amp;quot;bad&amp;quot; immune cell from clay, paint it and take it home as a souvenir.</gtr:impact><gtr:outcomeId>56c88da0101414.88779056</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://midlothiansciencefestival.com/event/mini-gala-day-newtongrange-library/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>183500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Marie Sklodowska-Curie Actions Individual Fellowships</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>NUMBER - 661369 - NanoMATe</gtr:fundingRef><gtr:id>7E6568CC-3520-4DE2-A602-60B46CD0E48E</gtr:id><gtr:outcomeId>55475a903e4fb3.54895327</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The dataset comprises of excel files containing the raw and processed data for Figures 2-7 in the manuscript. 

Figure 2 dataset is the excel spreadsheet that contains data that was analysed for the purpose to show the difference between using two different microtitre plates, known as Fluorotrac200 and Fluorotrac600.

Figure 3 is broken down into 3 datasets for the three rows (C, D and E) that were analysed using the Fluorotrac200 microtitre plate. Data used for Figure 4 is also conatined in the file 'Figure 3 Row C Data...'. This data represents the results when using the Fluorotrac200 to detect free cortisol in a sample. Both figures were to show the results obatined when detecting free cortisol in a sample. 

Figure 5 dataset has been saved as a zip file and contains three spreadsheets for the three rows analysed, to show the results obtained for the total cortisol quantitation assay. 

Figure 6 dataset included the raw and processed data for the total cortisol assay, showing two rows (C and D) using the Fluorotrac200 plate detecting the total cortisol present in a sample.

Figure 7 dataset contains the results obatined from using the Aushon chemiluminescence assay to form the basis of a comparison between this and the Raman method, all presented in an excel spreadsheet.

Data embargo until 10/08/17</gtr:description><gtr:id>59725268-7809-4AE7-A0D4-F3CF85933B05</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>58b982bab44616.05365942</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Detection of Cortisol in Serum Using Quantitative Resonance Raman Spectroscopy</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>&amp;quot;Chemometric analysis was performed on collected SERS spectra of fluorescence dyes and dye labelled DNA sequences to gain an insight on any form of preferential attachment that could occur in a multiplex SERS sample. Experimental parameters were altered to determine if these would effect any form of preferential attachment that was present.</gtr:description><gtr:id>566711BC-B861-4B3A-9705-433DADCA504E</gtr:id><gtr:impact>Not recorded</gtr:impact><gtr:outcomeId>56d83e0e3dcd40.38829545</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Preferential attachment of specific fluorescent dyes and dye labelled DNA sequences in a SERS multiplex</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EAEB0BE7-CF48-486A-9EFF-47E1F73D1977</gtr:id><gtr:title>Detection of cortisol in serum using quantitative resonance Raman spectroscopy</gtr:title><gtr:parentPublicationTitle>Analytical Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eefcbf72c34051f3029577cf4dfb09d"><gtr:id>5eefcbf72c34051f3029577cf4dfb09d</gtr:id><gtr:otherNames>Gracie K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>58b6ac7ba80696.64431496</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8421203E-4155-41E9-AC5F-F40905B1C082</gtr:id><gtr:title>The development of a three-dimensional culture system for in vitro studies of the atheroma</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9638b2ff7e3d12a1b3e6d969b0ba9c9"><gtr:id>c9638b2ff7e3d12a1b3e6d969b0ba9c9</gtr:id><gtr:otherNames>Noonan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56c87dfdcfc8d1.41086703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BCBECE0-9EB7-4672-B971-A1986858FEB1</gtr:id><gtr:title>Molecular imaging of atherosclerosis: spotlight on Raman spectroscopy and surface-enhanced Raman scattering.</gtr:title><gtr:parentPublicationTitle>Heart (British Cardiac Society)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd85f3e832d4f995458e5355174d1c00"><gtr:id>cd85f3e832d4f995458e5355174d1c00</gtr:id><gtr:otherNames>MacRitchie N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1355-6037</gtr:issn><gtr:outcomeId>59f890bdb0d989.75290253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>863245CE-7348-459D-B5BF-D0A1894878B0</gtr:id><gtr:title>Preferential Attachment of Specific Fluorescent Dyes and Dye Labeled DNA Sequences in a Surface Enhanced Raman Scattering Multiplex.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5eefcbf72c34051f3029577cf4dfb09d"><gtr:id>5eefcbf72c34051f3029577cf4dfb09d</gtr:id><gtr:otherNames>Gracie K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>56d8668d8fd385.59417253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0523480F-4880-4FD0-8821-3BDBE50215EC</gtr:id><gtr:title>Targeting inflammation to reduce cardiovascular disease risk.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd8e8c67e2894ea953a5b357e5b7ffe9"><gtr:id>bd8e8c67e2894ea953a5b357e5b7ffe9</gtr:id><gtr:otherNames>Maffia P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>59f890f7887bb6.91755859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6756090-E1F1-4301-8F53-6313C96AEA95</gtr:id><gtr:title>Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8863dbb4a5cd67ad1aaa3fd8259bffb6"><gtr:id>8863dbb4a5cd67ad1aaa3fd8259bffb6</gtr:id><gtr:otherNames>Welsh P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>594ea54dd08a98.42586928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64C02B08-434D-4957-88EE-5873E1D5D264</gtr:id><gtr:title>Mapping the Interaction of B Cell Leukemia 3 (BCL-3) and Nuclear Factor ?B (NF-?B) p50 Identifies a BCL-3-mimetic Anti-inflammatory Peptide.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/241fd04ca555ec524b0ef9b0366d9efd"><gtr:id>241fd04ca555ec524b0ef9b0366d9efd</gtr:id><gtr:otherNames>Collins PE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5a35f7a664e8b9.54163214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ADFA9F7-EE33-4B31-A864-48442B3289D0</gtr:id><gtr:title>Surface-Enhanced, Spatially Offset Raman Spectroscopy (SESORS) in Tissue Analogues.</gtr:title><gtr:parentPublicationTitle>ACS applied materials &amp; interfaces</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/287797e8cc54e190d7f2d570b3c1dd6f"><gtr:id>287797e8cc54e190d7f2d570b3c1dd6f</gtr:id><gtr:otherNames>Asiala SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1944-8244</gtr:issn><gtr:outcomeId>5a2fe111eb44c9.52498522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79717554-B8BE-414E-AC47-399ABB053CE8</gtr:id><gtr:title>Through barrier detection of ethanol using handheld Raman spectroscopy-Conventional Raman versus spatially offset Raman spectroscopy (SORS)</gtr:title><gtr:parentPublicationTitle>Journal of Raman Spectroscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2803b97bc374db96a2f405ad1b8717c8"><gtr:id>2803b97bc374db96a2f405ad1b8717c8</gtr:id><gtr:otherNames>Nicolson F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a2fea568659a9.23406774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F24450F8-FF18-4831-8D04-E1393EF044BF</gtr:id><gtr:title>Ferric plasmonic nanoparticles, aptamers, and magnetofluidic chips: toward the development of diagnostic surface-enhanced Raman spectroscopy assays.</gtr:title><gtr:parentPublicationTitle>Journal of biomedical optics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a353a01eaff64a3d677a35d2912075f"><gtr:id>9a353a01eaff64a3d677a35d2912075f</gtr:id><gtr:otherNames>Marks H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1083-3668</gtr:issn><gtr:outcomeId>58b7f60dba6616.94416670</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/L014165/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>863FC58A-7217-42EA-B076-663F2D770BB8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Chemical measurement</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>EB5F16BB-2772-4DDE-BD6C-3B7A6914B64C</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Info. &amp; commun. Technol.</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>DEA11FBC-BEED-4EDD-890B-97D728462D26</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Mathematical sciences</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>98EA7556-1427-44F9-84F3-BF99B7207302</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Analytical Science</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>02FE9751-1497-4DFD-B349-D4A9C96538E1</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Biophysics</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>0A982A4A-12CF-4734-AFCA-A5DC61F667F3</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Information &amp; Knowledge Mgmt</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>62309876-5C71-411C-B1A7-1B2907AFB5A8</gtr:id><gtr:percentage>15</gtr:percentage><gtr:text>Statistics &amp; Appl. Probability</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>